RANCHO CORDOVA, Calif.,
Sept. 5, 2018 /PRNewswire/
-- Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in
automated cell processing and point-of-care, autologous cell-based
therapies, announced today that is has sold X-LAB™ and/or X-WASH®
systems to four initial institutions/entities, and expects to end
2018 with a significant increase in the number of new
customers. Since the first formal exhibition of its X-Series
platform in May 2018, the Company has
received consistently positive feedback and interest in the product
line. Cesca will include a commercialization update during its
presentation at the upcoming HC Wainwright conference, on
September 6, 2018.
"Although sales of the X-Series instruments are one-time
transactions, each results in recurring sales of single-use
cartridges. We anticipate between 2,500 and 3,500 cartridge sales
from customers acquired in 2018," stated Chris Xu, PhD, chief executive officer of
Cesca.
Dr. Xu continued, "We are very encouraged by the response to our
X-Series platform and feel that the value is clearly resonating --
evidenced by the signing of these four initial customers, despite
not yet having a direct sales force in the field. Meanwhile, we are
currently in advanced discussions with potential distribution
partners for worldwide coverage. The need for automated cell
processing systems is great, and we are moving proactively to
expand our footprint within the industry. We look forward to
sharing our progress as we move forward."
Cesca's X-Series product offering currently includes:
- X-Lab for Cell Isolation – a semi-automated,
functionally-closed, ficoll-free system for the rapid isolation of
different target cells from various sources, including whole blood,
bone marrow aspirates and leukopheresis products.
- X-Wash for Washing and Reformulation – a
semi-automated, functionally-closed system that separates, washes,
and volume-reduces frozen cells or cell cultures to a programmable
volume. The cells of interest never leave the cartridge and
can be washed multiple times under lower centrifugation speeds
eliminating the creation of cell pellets.
- X-Mini™ cell selection kit for Research Only. The X-Mini
isolates targeted cell subsets from blood and blood products, and
is the first of several off-the-shelf kits
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc.
(the "Company") develops, commercializes and markets a range of
automated technologies for CAR-T and other cell-based therapies.
Its device division, ThermoGenesis Corp., provides a full suite of
solutions for automated clinical biobanking, point-of-care
applications, and automation for immuno-oncology. The Company is
developing an automated, functionally-closed CAR-TXpress™ platform
to streamline the manufacturing process for the emerging CAR-T
immunotherapy market.
Forward-Looking Statement
The statements contained
herein may include statements of future expectations and other
forward-looking statements that are based on management's current
views and assumptions and involve known and unknown risks and
uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. A more complete description of risks that could cause
actual events to differ from the outcomes predicted by Cesca
Therapeutics' forward-looking statements is set forth under the
caption "Risk Factors" in Cesca Therapeutics' annual report on Form
10-K and other reports it files with the Securities and Exchange
Commission from time to time, and you should consider each of those
factors when evaluating the forward-looking statements.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
ir@cescatherapeutics.com
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/cesca-therapeutics-provides-commercialization-update-for-its-x-series-product-line-300706886.html
SOURCE Cesca Therapeutics Inc.